Multi-indication Medicines

Multi-indication medicines highlight both the promise of scientific innovation and the need for thoughtful approaches to patient access.

Multi-indication medicines have the potential to transform care by addressing multiple conditions with a single therapy, often leveraging well-understood mechanisms of action and safety profiles. This approach can expand patient access to safe and effective treatment options.

While already common in oncology, multi-indication medicines continue to face significant challenges across the development and access pathway, from regulatory reviews to payer assessments and clinical adoption. As their use expands into other therapeutic areas, such as immunology and inflammation, these challenges are likely to become even more complex.

Timely and coordinated solutions will be essential to unlock the full potential of multi-indication medicines beyond oncology. A proactive, multi-stakeholder response is required to ensure these innovations can deliver maximum value for patients, health systems and society.

We have therefore been working on a project to address this topic.

Get involved

We invite you to complete a short questionnaire on the first version of the blueprint for a multi-year multi-indication (MYMI)-inspired access framework. The framework was co-created with a team of health economist experts as a potential solution for supporting the sustainable management of multi-indication medicines.

.

The MYMI-inspired access framework is a holistic approach to facilitate agreements for the reimbursement of a medicine’s current and future indications over several years. Rooted in the concept of the MYMI agreement – which has been recognised as having high potential with some real-world success – the framework aims to create a comprehensive approach to value assessment, pricing and reimbursement, with flexibility for local adaptation. Your input will help refine the scope and content of the blueprint and understand the implementation feasibility of such a framework.

We would greatly appreciate your perspectives.

Complete questionnaire here

See framework overview

View here

See framework blueprint

View here

Completed work

Activities to date include:

  • Literature review and expert interviews to answer the following research questions:
    • What is the key value of multiple indication products recognised in the literature?
    • What are the current access policies and regulations for multiple indication products in EU4 + UK?
    • What are the key P&R challenges for multiple indication products currently experienced in EU4 + UK in practice, within the existing policy systems?
    • What are the recommended best practices / potential solutions?
  • Wider engagement through a panel and stakeholder engagement with ~800 participants at ISPOR Europe 2024
  • Alignment on the MYMI concept and elements required for implementation, with insights gathered through a questionnaire and live discussions with 7 health economist experts
  • Co-creation of blueprint for a MYMI-inspired access framework with the health economist group

Disclaimer: work and deliverables to date have been funded by argenx

Deliverables to date

Disclaimer: work and deliverables to date have been funded by argenx

Invitation to participate

We are working to collaborate and understand from all stakeholders’ perspectives what feasible solutions for multi-indication medicines could look like. As this work has evolved, we recognise the need to create a wider consortium that can contribute to and help drive the conversation on this important topic.

If you would like to be kept updated, collaborate or express interest as an industry sponsor, please visit:

Invitation to participate